Current status: Answered by Maree Todd on 22 September 2026
To ask the Scottish Government whether it will consider introducing a proactive screening programme for prostate cancer for men who carry the BRCA1 or BRCA2 gene variants.
Scotland follows the advice of the UK National Screening Committee (UK NSC), the independent expert body that advises all four UK nations on screening programmes.
On 28 May 2026, the UK NSC recommended that prostate screening should be offered to men aged 45 to 61 who have both a confirmed BRCA2 gene variant and a family history of breast, ovarian, pancreatic or prostate cancer. We have accepted this recommendation and are strengthening existing high-risk surveillance pathways for prostate cancer, which already enable eligible men to access testing in line with the UK NSC's recommendation. The recently established Prostate Screening Working Group are also considering what is required to develop a nationally managed prostate screening programme.
After closely examining the existing evidence around screening men with the BRCA1 variant, or men with a BRCA2 variant without a family history of associated cancers, the UK NSC currently does not recommend prostate screening for these groups. It has found that there is not yet a suitably accurate test for a national screening programme of asymptomatic men, and there is currently insufficient evidence that the benefits of screening outweigh the risks for other higher risk groups.
However the UK NSC is monitoring emerging evidence closely and will consider whether new evidence supports expanding their recommended eligibility criteria for prostate cancer screening. In recognition that the UK NSC may expand their recommendation in the future, we are exploring what would be required to extend prostate cancer screening to other groups. Should they recommend screening all men with a BRCA1 or 2 variant, we would work with the NHS to take that forward in Scotland.